Natural Killer Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Natural Killer Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Combination With Romidepsin [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pembrolizumab in combination with romidepsin for recurrent or refractory T-cell lymphomas; the study i…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant [Phase 1, Phase 2]
This update reports results from a Phase 1/2 clinical trial of a gene therapy for HIV-related lymphomas in patients undergoing stem cell tra…
-
CLINICAL_TRIALS trial_result · 2022-05-17Clinical Trial Update: Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment [Phase 1, Phase 2]
Clinical trial update on clofarabine in relapsed or refractory T-cell or NK-cell non-Hodgkin's lymphoma (Phase 1/2) completed with posted re…
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for YY-20394 in relapsed or refractory peripheral T-cell/NK-cell lymphoma (PTCL).
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies [Phase 1, Phase 2]
A multi-CAR T therapy targeting CD7 is being studied in Phase 1/Phase 2 for CD7-positive malignancies including T-cell acute lymphoblastic l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-01-28Clinical Trial Update: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas [Phase 1]
Phase 1 study of alisertib plus romidepsin in relapsed or refractory B-cell and T-cell lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms [Phase 1]
Phase 1 study of brentuximab vedotin given sequentially and in combination with multi-agent chemotherapy for CD30-positive mature T-cell and…
-
CLINICAL_TRIALS trial_result · 2014-08-25Clinical Trial Update: Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma [Phase 2]
This Phase 2 trial update describes BuEAM conditioning with busulfan, etoposide, cytarabine, and melphalan before autologous stem cell trans…
-
CLINICAL_TRIALS trial_result · 2013-09-23Clinical Trial Update: Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies [Phase 1]
A Phase 1 study of oral forodesine hydrochloride (BCX-1777) in patients with recurrent or refractory T/NK-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2008-10-22Clinical Trial Update: Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma [Phase 1]
Phase 1 study evaluating CHOP chemotherapy in combination with Campath (alemtuzumab) for T-cell lymphoma, NK-cell lymphoma, and other non-Ho…